PFE FY 2017 Earnings Report — Pfizer Inc. Revenue & Financial Results | Market Cap Arena

FY 2017 Earnings

Reported February 22, 2018

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2017	Prior Q	FY 2016	QoQ Change	YoY Change
Revenue	$52.5B	—	$52.8B	—	-0.5%
Op. Income	$14.4B	—	$14.3B	—	0.8%
Gross Margin	70.0%	—	69.8%	—	0.2pp
Net Margin	40.5%	—	13.7%	—	26.9pp
EPS (Diluted)	$3.52	—	$1.17	—	200.6%
Free Cash Flow	$14.3B	—	$13.9B	—	2.5%

Revenue Flow

Item	Amount
REVENUE	$52.5B
Cost of Revenue	$15.8B
GROSS PROFIT	$36.8B
R&D Expenses	$7.6B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$14.7B
Other Expenses	$0
Operating Expenses	$22.4B
Cost & Expenses	$38.2B
OPERATING INCOME	$14.4B
Interest Income	$391M
Interest Expense	$1.3B
Other Income/Expenses	-$2.1B
INCOME BEFORE TAX	$12.3B
Income Tax Expense	-$9.0B
Net Income from Continuing Ops	$21.4B
Net Income from Discontinued Ops	-$1M
Other Adjustments	$0
NET INCOME	$21.3B
Net Income Deductions	-$1M
BOTTOM LINE NET INCOME	$21.3B
D&A	$6.3B
EBIT	$13.6B
EBITDA	$19.8B
EPS	$4
EPS Diluted	$4

Income Statement

Item	Amount
REVENUE	$52.5B
Cost of Revenue	$15.8B
GROSS PROFIT	$36.8B
R&D Expenses	$7.6B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$14.7B
Other Expenses	$0
Operating Expenses	$22.4B
Cost & Expenses	$38.2B
OPERATING INCOME	$14.4B
Interest Income	$391M
Interest Expense	$1.3B
Other Income/Expenses	-$2.1B
INCOME BEFORE TAX	$12.3B
Income Tax Expense	-$9.0B
Net Income from Continuing Ops	$21.4B
Net Income from Discontinued Ops	-$1M
Other Adjustments	$0
NET INCOME	$21.3B
Net Income Deductions	-$1M
BOTTOM LINE NET INCOME	$21.3B
D&A	$6.3B
EBIT	$13.6B
EBITDA	$19.8B
EPS	$4
EPS Diluted	$4

Cash Flow Statement

Item	Amount
Net Income	$21.4B
Depreciation & Amortization	$6.3B
Stock-Based Compensation	$840M
Deferred Income Tax	-$2.4B
Other Non-Cash Items	-$10.9B
Change in Working Capital	$1.3B
OPERATING CASH FLOW	$16.5B
Capital Expenditure	-$2.2B
Acquisitions (Net)	-$1.0B
Purchases of Investments	-$18.1B
Sales/Maturities of Investments	$16.0B
Other Investing Activities	$650M
NET CASH FROM INVESTING	-$4.7B
Net Debt Issuance	-$941M
Common Stock Repurchased	-$5.0B
Common Dividends Paid	-$7.7B
Other Financing Activities	$250M
NET CASH FROM FINANCING	-$13.0B
FREE CASH FLOW	$14.3B
Net Change in Cash	-$1.3B

Balance Sheet

Item	Amount
Cash & Equivalents	$1.3B
Short-Term Investments	$18.6B
Net Receivables	$11.3B
Inventory	$7.6B
Other Current Assets	$2.3B
TOTAL CURRENT ASSETS	$41.1B
PP&E (Net)	$13.9B
Goodwill	$56.0B
Intangible Assets	$48.7B
Long-Term Investments	$7.0B
Tax Assets	$1.9B
Other Non-Current Assets	$3.2B
TOTAL NON-CURRENT ASSETS	$130.7B
TOTAL ASSETS	$171.8B
Account Payables	$4.7B
Short-Term Debt	$9.9B
Deferred Revenue	$0
Other Current Liabilities	$13.3B
TOTAL CURRENT LIABILITIES	$30.4B
Long-Term Debt	$32.7B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$3.9B
Other Non-Current Liabilities	$33.1B
TOTAL NON-CURRENT LIABILITIES	$69.7B
TOTAL LIABILITIES	$100.1B
Common Stock	$464M
Additional Paid-In Capital	$84.3B
Retained Earnings	$85.3B
Treasury Stock	-$89.4B
Accum. Other Comp. Income	-$9.3B
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$71.3B
Minority Interest	$348M
TOTAL EQUITY	$71.7B
TOTAL LIABILITIES & EQUITY	$171.8B
Total Debt	$42.6B
Net Debt	$41.3B